Impact of ABCB1 Polymorphism on Levetiracetam Serum Concentrations in Epileptic Uygur Children in China
Open Access
- 1 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 42 (6) , 886-892
Abstract
Background: Interindividual variations in the efficacy of antiseizure medications make epilepsy treatment challenging. This is due to genetic factors such as gene polymorphisms in Adenosine-triphosphate (ATP)-binding cassette sub-family B member 1 (ABCB1). In this article, the impact of polymorphisms in the P-glycoprotein-encoding gene, ABCB1 (C1236T, G2677T/A, and C3435T), on levetiracetam disposition was evaluated in Uygur Chinese children with epilepsy. Methods: MDR1 C3435T polymorphism was analyzed by polymerase chain reaction–fluorescence staining in situ hybridization. The χ2 test and Fisher exact test were used to analyze the allelic and genotypic distribution of ABCB1, C1236T, G2677T, and C3435T between the drug-resistant and drug-responsive groups. Differences in steady-state and dose-corrected levetiracetam serum concentrations between the different genotypes were analyzed using 1-way analysis of variance and Mann–Whitney test. Results: Total 245 Uygur children with epilepsy were analyzed [drug-resistant, n = 117 (males:females = 53:64) and drug-responsive, n = 128 (males:females = 76:52)]. The frequency of ABCB1 C1236T, G2677T/A, and ABCB1 C3435T genotypes, alleles, haplotypes, or diplotypes did not differ significantly between the 2 groups (P > 0.05). Significantly higher levetiracetam concentrations and serum concentration/body mass dose were seen in ABCB1 2677-GT, TT, GA, and AT genotypes and 3435-TT carriers compared with GG and CC carriers (P = 0.021 and P = 0.002 versus P = 0.001 and P = 0.000, respectively). Conclusions: ABCB1 G2677T/A and C3435T may affect levetiracetam disposition and therapeutic efficacy in Uygur children with epilepsy. Genetic analysis could be a valuable tool for predicting the response to antiseizure medications before the start of treatment and could contribute to personalized medicine for Uygur children with epilepsy.Keywords
This publication has 31 references indexed in Scilit:
- Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: An analysis in a western Chinese pediatric populationBrain Research, 2011
- Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsyEpilepsy & Behavior, 2011
- Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic StrategiesEpilepsia, 2010
- The clinical impact of pharmacogenetics on the treatment of epilepsyEpilepsia, 2009
- ABC Transporters during Epilepsy and Mechanisms Underlying Multidrug Resistance in Refractory EpilepsyEpilepsia, 2007
- Multidrug resistance in epilepsy: a pharmacogenomic updateExpert Opinion on Pharmacotherapy, 2007
- Pharmacokinetics of Levetiracetam in Infants and Young Children with EpilepsyEpilepsia, 2007
- SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism lociCell Research, 2005
- Clinical Pharmacokinetics of LevetiracetamClinical Pharmacokinetics, 2004
- Guidelines for Clinical Evaluation of Antiepileptic DrugsEpilepsia, 1989